Home/Filings/4/0000899243-20-001539
4//SEC Filing

GREEN JOHN B 4

Accession 0000899243-20-001539

CIK 0001399529other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 8:00 PM ET

Size

16.1 KB

Accession

0000899243-20-001539

Insider Transaction Report

Form 4
Period: 2020-01-17
GREEN JOHN B
Interim CFO
Transactions
  • Sale

    Common Stock

    2020-01-17$21.27/sh27,500$584,93639,890 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2020-01-1727,50047,500 total
    Exercise: $2.97Exp: 2027-01-03Common Stock (27,500 underlying)
  • Exercise/Conversion

    Common Stock

    2020-01-17$2.97/sh+20,469$60,79367,390 total
  • Exercise/Conversion

    Common Stock

    2020-01-17$2.97/sh+27,500$81,67546,921 total
  • Sale

    Common Stock

    2020-01-17$21.26/sh20,469$435,22819,421 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2020-01-1720,46927,031 total
    Exercise: $2.97Exp: 2027-01-03Common Stock (20,469 underlying)
Footnotes (6)
  • [F1]Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
  • [F2]The reporting person sold an aggregate of 47,969 shares of common stock on January 17, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 6.78% of 707,021 shares of common stock, which is the number of shares of common stock owned by the reporting person prior to the Shares Sold transactions reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the reporting person as of the date of this report.
  • [F3]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2019.
  • [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.10 to $21.51, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
  • [F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.10 to $21.51, inclusive. The reporting person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
  • [F6]The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date.

Issuer

Dicerna Pharmaceuticals Inc

CIK 0001399529

Entity typeother

Related Parties

1
  • filerCIK 0001243847

Filing Metadata

Form type
4
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 8:00 PM ET
Size
16.1 KB